A proteomic approach for the identification of biomarkers in endometrial cancer uterine aspirate
Metrics: PDF 763 views | HTML 1760 views | ?
Blendi Ura1, Lorenzo Monasta1, Giorgio Arrigoni2,3, Cinzia Franchin2,3, Oriano Radillo1, Isabel Peterlunger1, Giuseppe Ricci1,4 and Federica Scrimin1
1Institute for Maternal and Child Health-IRCCS “Burlo Garofolo”, Trieste, Italy
2Department of Biomedical Sciences, University of Padova, Padova, Italy
3Proteomics Center, University of Padova and Azienda Ospedaliera di Padova, Padova, Italy
4Department of Medical, Surgery and Health Sciences, University of Trieste, Trieste, Italy
Blendi Ura, email: firstname.lastname@example.org
Keywords: endometrial neoplasms; uterine aspirate; two dimensional electrophoresis; mass spectrometry; biomarkers
Received: May 30, 2017 Accepted: November 01, 2017 Published: November 30, 2017
Endometrial cancer arises from the endometrium. It has a slow progression and a reported survival rate of 75%. The identification of soluble biomarkers in the uterine aspirate may be very useful for its early diagnosis. Uterine aspirates from 10 patients with endometrial cancer and 6 non-endometrial cancer controls were analyzed by two-dimensional gel electrophoresis coupled with mass spectrometry and western blotting for data verification. A total of 25 proteins with fold change in %V ≥2 or ≤0.5 in intensity were observed to change significantly (P<0.05). From the discovery phase, four proteins (costars family protein ABRACL, phosphoglycerate mutase 2, fibrinogen beta chain, annexin A3) were found to be present in the uterine aspirate of endometrial cancers and not in healthy aspirates. Western blotting verification data demonstrated that costars family protein ABRACL, phosphoglycerate mutase 2 were present only in endometrial cancer uterine aspirate while fibrinogen beta chain, annexin A3 were also present in healthy aspirates. To our knowledge, phosphoglycerate mutase 2 has not been previously associated with endometrial cancer. In this study we demonstrate that uterine aspirates are a promising biological fluid in which to identify endometrial cancer biomarkers. In our opinion proteins like costars family protein ABRACL and phosphoglycerate mutase 2 have a great potential to reach the clinical phase after a validation phase.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.